Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NKTR Nektar Therapeutics

Market Closed 08-07 16:00:00 EDT

76.48

+3.03

+4.13%

盘后75.46

-1.02-1.33%

19:59 EDT

High77.00	Low73.18	Vol899.16K
Open74.55	D1 Closing73.45	Amplitude5.20%
Mkt Cap2.58B	Tradable Cap2.23B	Total Shares33.74M
T/O67.94M	T/O Rate3.09%	Tradable Shares29.14M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NKTR","market":"US","secType":"STK","nameCN":"Nektar Therapeutics","latestPrice":76.48,"timestamp":1786132800000,"preClose":73.45,"halted":0,"volume":899157,"hourTrading":{"tag":"盘后","latestPrice":75.46,"preClose":76.48,"latestTime":"19:59 EDT","volume":20932,"amount":1598762.786,"timestamp":1786147196562,"change":-1.02,"changeRate":-0.013337,"amplitude":0.020109},"delay":0,"changeRate":0.04125255275697755,"floatShares":29136100,"shares":33742100,"eps":-8.095877,"marketStatus":"Market Closed","change":3.03,"latestTime":"08-07 16:00:00 EDT","open":74.55,"high":77,"low":73.18,"amount":67936607.38473001,"amplitude":0.052008,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.095877,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786348800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":73.45,"preHourTrading":{"tag":"盘前","latestPrice":74.59,"preClose":73.45,"latestTime":"09:29 EDT","volume":1557,"amount":114855.14115,"timestamp":1786109399516,"change":1.14,"changeRate":0.015521,"amplitude":0.039346},"postHourTrading":{"tag":"盘后","latestPrice":75.46,"preClose":76.48,"latestTime":"19:59 EDT","volume":20932,"amount":1598762.786,"timestamp":1786147196562,"change":-1.02,"changeRate":-0.013337,"amplitude":0.020109},"volumeRatio":1.5989567162914107,"optionData":{"bulkOrders":[{"symbol":"NKTR","call":true,"expireDate":1789704000000,"strike":"100.0","timestamp":1786124879925,"price":0.95,"volume":4452,"amount":422940,"type":"+"}]},"impliedVol":0.7158,"impliedVolPercentile":0.3586},"requestUrl":"/m/hq/s/NKTR","defaultTab":"news","newsList":[{"id":"1157096629","title":"Earning Preview: Nektar Therapeutics revenue expected to decrease by 3.91%, and institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1157096629","media":"Earnings Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1157096629?lang=en_us&edition=fundamental","pubTime":"2026-08-06 12:51","pubTimestamp":1785991876,"startTime":"0","endTime":"0","summary":"Abstract Nektar Therapeutics will release quarterly results on August 13, 2026 (Post-Mkt), with consensus indicating this quarter’s revenue near 10.42 million US dollars, adjusted EPS around -1.99,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Earning Preview: Nektar Therapeutics revenue expected to decrease by 3.91%, and institutional views are bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655835123","title":"Nektar Therapeutics to Report Q2 Results After U.S. Market Close, Hosts Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2655835123","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655835123?lang=en_us&edition=fundamental","pubTime":"2026-07-29 06:00","pubTimestamp":1785276023,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics to report Q2 results after U.S. market close, hosts conference callNektar Therapeutics schedules Q2 2026 results for Aug. 13, 2026, released post-close.Results conference call set ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL2CSnV6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654471090","title":"Is Nektar Therapeutics (NKTR) Undervalued On Its Phase 3 Rezpegaldesleukin Launch?","url":"https://stock-news.laohu8.com/highlight/detail?id=2654471090","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654471090?lang=en_us&edition=fundamental","pubTime":"2026-07-28 02:23","pubTimestamp":1785176602,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NKTR) has launched the first two global Phase 3 ZENITH AD trials for rezpegaldesleukin in moderate to severe atopic dermatitis, supported by earlier Phase 2b data and FDA Fast Track designations.\nSee our latest analysis for Nektar Therapeutics.\nThe latest rezpegaldesleukin Phase 3 launch comes after a sharp shift in sentiment around Nektar Therapeutics, with a 1-year total shareholder return of 199.05% and a year to date share price return of 62.89%. However, momentum has...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/is-nektar-therapeutics-nktr-undervalued-on-its-phase-3-rezpe","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/is-nektar-therapeutics-nktr-undervalued-on-its-phase-3-rezpe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654030868","title":"Nektar Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654030868","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654030868?lang=en_us&edition=fundamental","pubTime":"2026-07-25 05:33","pubTimestamp":1784928802,"startTime":"0","endTime":"0","summary":"BRIEF-Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)July 24 (Reuters)-Nektar TherapeuticsNKTR.O:NEKTAR THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)Source text:ID:nPn5vrFF1aFurther company coverage:NKTR.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nTUA99WT6P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654329010","title":"Nektar Grants 36,000 Inducement Stock Options Priced at $64.84 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2654329010","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654329010?lang=en_us&edition=fundamental","pubTime":"2026-07-25 04:15","pubTimestamp":1784924129,"startTime":"0","endTime":"0","summary":"Nektar grants 36,000 inducement stock options priced at $64.84 per shareNektar Therapeutics granted non-qualified stock options covering 36,000 shares to 23 newly hired employees on July 20, 2026.Opti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDL2sdshz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653719909","title":"Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nektar Therapeutics (NKTR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653719909","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653719909?lang=en_us&edition=fundamental","pubTime":"2026-07-23 13:50","pubTimestamp":1784785838,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nek...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-johnson-johnson-jnj-helus-pharma-help-and-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-johnson-johnson-jnj-helus-pharma-help-and-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE000MB6IJN5.SGD","BK4532","IXJ","PJP","IE00B4R5TH58.HKD","HELP","LU0124676726.USD","LU1196500208.SGD","LU0053666078.USD","LU1244550221.USD","LU0234572021.USD","LABU","LU0345769631.USD","IE00B3PB1722.GBP","LU0029874061.USD","IE00BSNM7G36.USD","BMED","LU0689626769.HKD","JNJ","FHLC","IE00B42XCP33.USD","NKTR","HCSG","IE000BZT7R73.USD","LU0882574055.USD","LU0162691827.USD","XBI","GDOC","IHE","IYH","LU1162221912.USD","LU0683600562.USD","LU1032955483.USD","IE00BGHQF631.EUR","LU1629891620.HKD","TRUH","XLV","VHT","SGXZ57979304.SGD","FTXH","LU2602419157.SGD","JDOC","LU1074936037.SGD","LU1674673691.USD","LU1718418525.SGD","LU0210536198.USD","RXL","LU0787776722.HKD","LU0820561909.HKD","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653633267","title":"Nektar Therapeutics : Canaccord Genuity Initiates Coverage with Buy Rating; Target Price $153","url":"https://stock-news.laohu8.com/highlight/detail?id=2653633267","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653633267?lang=en_us&edition=fundamental","pubTime":"2026-07-22 21:18","pubTimestamp":1784726307,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nFWN43O0Y6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653752991","title":"Nektar Therapeutics Initiated at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2653752991","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653752991?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:21","pubTimestamp":1784719260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTR/analyst-ratings(END) Dow Jones NewswiresJuly 22, 2026 07:21 ET","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653930752","title":"Cantor Fitzgerald Initiates Nektar Therapeutics at Buy With $153 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2653930752","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653930752?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:18","pubTimestamp":1784719097,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NKTR) has an average rating of buy and mean price target of $153.22, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653716212","title":"Nektar Therapeutics Announces Press Release on Start of Phase 3 Zenith AD Program for Rezpegaldesleukin in Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2653716212","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653716212?lang=en_us&edition=fundamental","pubTime":"2026-07-21 19:02","pubTimestamp":1784631768,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics announces press release on start of Phase 3 ZENITH AD program for rezpegaldesleukin in atopic dermatitisNektar published a press release announcing the start of its Phase 3 ZENITH ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL9cJtQY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653271592","title":"Nektar Therapeutics - Zenith Ad Program to Enroll 1,530 Patients Across Three Phase 3 Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2653271592","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653271592?lang=en_us&edition=fundamental","pubTime":"2026-07-21 19:00","pubTimestamp":1784631611,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nFWN43N07D:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653271566","title":"Nektar Therapeutics Announces Start of Phase 3 Zenith Ad Program Evaluating Novel Regulatory T-cell Biologic Rezpegaldesleukin in Moderate-to-severe Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2653271566","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653271566?lang=en_us&edition=fundamental","pubTime":"2026-07-21 19:00","pubTimestamp":1784631611,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nFWN43N07D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653271531","title":"Nektar Therapeutics - Initial Phase 3 Topline Data Expected Mid-2028; Bla Submission Targeted for 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2653271531","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653271531?lang=en_us&edition=fundamental","pubTime":"2026-07-21 19:00","pubTimestamp":1784631611,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nFWN43N07D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652787261","title":"Nektar Therapeutics (NKTR) Stock Looks Above Fair Value Despite Its 7x Run","url":"https://stock-news.laohu8.com/highlight/detail?id=2652787261","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652787261?lang=en_us&edition=fundamental","pubTime":"2026-07-20 11:24","pubTimestamp":1784517868,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics has produced very strong share price gains over the last three years, yet on Simply Wall St’s broader checks it screens as expensive rather than a clear bargain. This puts the recent rally under scrutiny for valuation focused investors.\n\nThe stock has returned roughly 7x over three years, which makes it important to question how much future potential is already reflected in the current share price.\nExpectations around Nektar Therapeutics' ability to translate its pipeline...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-stock-looks-above-fair-value-despit","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-stock-looks-above-fair-value-despit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","NKTR","TSPA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652228406","title":"Nektar’s Phase 3 Eczema Bet: What Rezpegaldesleukin Could Mean for NKTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2652228406","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652228406?lang=en_us&edition=fundamental","pubTime":"2026-07-18 00:31","pubTimestamp":1784305895,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics ($NKTR) announced an update on their ongoing clinical study. Nektar Therapeutics is running a Phase 3 study called “A Phase 3 S...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nektars-phase-3-eczema-bet-what-rezpegaldesleukin-could-mean-for-nktr-stock?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nektars-phase-3-eczema-bet-what-rezpegaldesleukin-could-mean-for-nktr-stock?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649643971","title":"Nektar Therapeutics (NKTR) Advances Autoimmune Pipeline, Is The Upside Already Priced In?","url":"https://stock-news.laohu8.com/highlight/detail?id=2649643971","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649643971?lang=en_us&edition=fundamental","pubTime":"2026-07-06 10:24","pubTimestamp":1783304690,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NKTR) is back in focus after positive mid stage data in alopecia areata and plans to start late stage trials in atopic dermatitis, raising questions about what the pipeline could mean for the stock.\nSee our latest analysis for Nektar Therapeutics.\nNektar Therapeutics’ recent 10.3% 1 day share price return to US$71.04 and 23.9% 1 month share price return suggest momentum has picked up again, alongside index inclusions and fresh enthusiasm around its autoimmune pipeline,...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-advances-autoimmune-pipeline-is-the","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-advances-autoimmune-pipeline-is-the","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648463948","title":"Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky Sells 5,681 Shares for $397,670","url":"https://stock-news.laohu8.com/highlight/detail?id=2648463948","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648463948?lang=en_us&edition=fundamental","pubTime":"2026-07-03 07:07","pubTimestamp":1783033645,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky sells 5,681 shares for $397,670Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky sold 5,681 common shares on June 30, 2026 at $70.He repor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL5p0X1l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky Sells 5,681 Shares for $397,670","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646360131","title":"Nektar Grants New Hires Options for 20,500 Shares at $60.98 Each Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2646360131","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646360131?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:30","pubTimestamp":1782505813,"startTime":"0","endTime":"0","summary":"Nektar grants new hires options for 20,500 shares at $60.98 each under inducement planNektar Therapeutics granted inducement equity awards to seven new hires on June 19, 2026 under its 2025 Inducement","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL6sWS6d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646609443","title":"Nektar Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646609443","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646609443?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:30","pubTimestamp":1782505800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nTUA2CFVNS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644347050","title":"Nektar Therapeutics CEO Robin Howard sells USD 1.2 million in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2644347050","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644347050?lang=en_us&edition=fundamental","pubTime":"2026-06-19 07:09","pubTimestamp":1781824147,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics President and CEO W. Robin Howard sold 20,000 common shares on June 16-17.Sales priced at USD 59.97 to USD 61.65 per share.Direct holdings fell to 55,045 shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL74P0Ym:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nektar Therapeutics CEO Robin Howard sells USD 1.2 million in common shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nektar.com","stockEarnings":[{"period":"1week","weight":0.0822},{"period":"1month","weight":0.0637},{"period":"3month","weight":-0.0661},{"period":"6month","weight":1.0777},{"period":"1year","weight":2.5163},{"period":"ytd","weight":0.8089}],"compareEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":0.0374},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1197},{"period":"1year","weight":0.223},{"period":"ytd","weight":0.1339}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.03787},{"month":2,"riseRate":0.53125,"avgChangeRate":0.029488},{"month":3,"riseRate":0.40625,"avgChangeRate":-0.000642},{"month":4,"riseRate":0.46875,"avgChangeRate":0.016904},{"month":5,"riseRate":0.34375,"avgChangeRate":-0.004399},{"month":6,"riseRate":0.424242,"avgChangeRate":0.026471},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.018591},{"month":8,"riseRate":0.484848,"avgChangeRate":0.046018},{"month":9,"riseRate":0.5,"avgChangeRate":0.042479},{"month":10,"riseRate":0.375,"avgChangeRate":-0.023288},{"month":11,"riseRate":0.6875,"avgChangeRate":0.087128},{"month":12,"riseRate":0.59375,"avgChangeRate":0.015542}],"exchange":"NASDAQ","name":"Nektar Therapeutics","nameEN":"Nektar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nektar Therapeutics,NKTR,Nektar Therapeutics股票,Nektar Therapeutics股票老虎,Nektar Therapeutics股票老虎国际,Nektar Therapeutics行情,Nektar Therapeutics股票行情,Nektar Therapeutics股价,Nektar Therapeutics股市,Nektar Therapeutics股票价格,Nektar Therapeutics股票交易,Nektar Therapeutics股票购买,Nektar Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}